statistiche per PERALDO NEIA, CATERINA

Distribuzione geografica

Nome	#
Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer	110
Preclinical activity of EGFR and MEK1/2 inhibitors in the treatment of biliary tract carcinoma	109
Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models.	96
Establishment of a patient-derived intrahepatic cholangiocarcinoma xenograft model with KRAS mutation.	80
Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma	76
Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas	70
HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib	51
Screening for the FIG-ROS1 fusion in biliary tract carcinomas by nested PCR.	34
Establishment and characterization of a human intrahepatic cholangiocarcinoma cell line derived from an Italian patient	33
Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer.	28
A new pro-apoptotic therapy for Acute Myeloid Leukaemia using MEDS433, a potent human Dihydroorotate Dehydrogenase inhibitor	7
Totale	694

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2016/2017	28	0	0	0	0	0	0	0	0	0	0	28	0
2017/2018	100	1	13	14	2	0	2	6	13	37	10	1	1
2018/2019	116	2	1	2	6	3	7	5	15	5	20	37	13
2019/2020	179	8	12	7	30	14	27	24	15	9	22	8	3
2020/2021	101	4	5	8	9	2	10	5	7	10	11	3	27
2021/2022	116	11	14	8	14	4	1	6	5	0	12	41	0
Totale													694

CINECA IRIS Institutional Research Information System